Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:08:20.611Z.
Calculation as of: 2026-10-06T17:08:20.611Z.
Quote observation: 2026-10-06T17:05:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9eb175beb73ea6d5bc2b5d4e57ff3726ad64c6dbf03440990cee379981bf6545
PE RATIO
N/A
Market Cap
$30755.00
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6039.00
PE Ratio
N/A
TTM Avg
3571.19
3Y Avg
5980.81
5Y Avg
5980.81
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Psyence Biomedical Ltd. (PBM) | $95285.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $109065.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $72318.00 | N/A | N/A | N/A | N/A |
| Akanda Corp. (AKAN)vs › | $61819.00 | N/A | N/A | N/A | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30755.00 | N/A | N/A | N/A | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6039.00 | N/A | 3571.19 | 5980.81 | 5980.81 |
| SciSparc Ltd. (SPRC)vs › | $243502.00 | N/A | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $381125.00 | N/A | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $487356.00 | N/A | 1.51 | 1.33 | 1.33 |
| HCW Biologics Inc. (HCWB)vs › | $556226.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
